Dacarbazine – Uses, Dosage, Side Effects, Interactions

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 57 min read

Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

Patient Mode

Understand this article easily

Switch between simple English and easy Bangla patient notes. This is for education and does not replace a doctor consultation.

For severe symptoms, danger signs, pregnancy, child illness, or sudden worsening, seek urgent medical care.

বাংলা রোগী নোট এখনো যোগ করা হয়নি। পোস্ট এডিটরে “RX Bangla Patient Mode” বক্স থেকে সহজ বাংলা সারাংশ যোগ করুন।

এই তথ্য শিক্ষা ও সচেতনতার জন্য। এটি ডাক্তারি পরীক্ষা, রোগ নির্ণয় বা প্রেসক্রিপশনের বিকল্প নয়।

Article Summary

Dacarbazine (also known as DTIC) is an intravenously administered alkylating agent used in the therapy of Hodgkin's disease and malignant melanoma. Dacarbazine therapy has been associated with serum enzyme elevations during therapy and occasional cases of severe and distinctive acute hepatic failure, probably caused by acute sinusoidal obstruction syndrome. Dacarbazine is a triazene derivative with antineoplastic activity. Dacarbazine alkylates and cross-links DNA during all phases of...

Key Takeaways

This article explains Mechanism of Action in simple medical language.
This article explains Indications in simple medical language.
This article explains Contraindications in simple medical language.
This article explains Dosage in simple medical language.

Educational health guideWritten for patient understanding and clinical awareness.

Reviewed content workflowUse writer and reviewer profiles for stronger trust.

Emergency safety firstUrgent warning signs are highlighted below.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

Severe symptoms, breathing difficulty, fainting, confusion, or rapidly worsening illness.
New weakness, severe pain, high fever, or symptoms after a serious injury.
Any symptom that feels urgent, unusual, or unsafe for the patient.

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.

Definition

Dacarbazine (also known as DTIC) is an intravenously administered alkylating agent used in the therapy of Hodgkin’s disease and malignant melanoma. Dacarbazine therapy has been associated with serum enzyme elevations during therapy and occasional cases of severe and distinctive acute hepatic failure, probably caused by acute sinusoidal obstruction syndrome.

Dacarbazine is a triazene derivative with antineoplastic activity. Dacarbazine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis. (NCI04)

Dacarbazine appears as white to ivory microcrystals or off-white crystalline solids. (NTP, 1992). Dacarbazine (also known as DTIC) is an intravenously administered alkylating agent used in the therapy of Hodgkin’s disease and malignant melanoma. Dacarbazine therapy has been associated with serum enzyme elevations during therapy and occasional cases of severe and distinctive acute hepatic failure, probably caused by acute sinusoidal obstruction syndrome.

Mechanism of Action

The mechanism of action is not known but appears to exert cytotoxic effects via its action as an alkylating agent. Other theories include DNA synthesis inhibition by its action as a purine analog and interaction with SH groups. Dacarbazine is not celled cycle-phase specific.

Dacarbazine functions as an alkylating agent after metabolic activation in the liver. It appears to inhibit the synthesis of RNA and protein more than it inhibits the synthesis of DNA. It kills cells slowly, and there appears to be no phase of the cell cycle in which sensitivity is increased

Dacarbazine is a synthetic analog of naturally occurring purine precursor 5-amino-1H-imidazole-4-carboxamide (AIC). After intravenous administration of dacarbazine, the volume of distribution exceeds total body water content suggesting localization in some body tissue, probably the liver. Its disappearance from the plasma is biphasic with an initial half-life of 19 minutes and a terminal half-life of 5 hours. 1 In a patient with renal and hepatic dysfunctions, the half-lives were lengthened to 55 minutes and 7.2 hours. 1 The average cumulative excretion of unchanged DTIC in the urine is 40% of the injected dose in 6 hours. 1 DTIC is subject to renal tubular secretion rather than glomerular filtration. At therapeutic concentrations, dacarbazine is not appreciably bound to human plasma protein.

Indications

For the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin’s disease as a secondary-line therapy when used in combination with other antineoplastic agents.
Hodgkin lymphoma in patients whose disease has not gotten better with other chemotherapy.
Melanoma that has metastasized(spread to other parts of the body).
Dacarbazine is also being studied in the treatment of other types of cancer.
Dacarbazine is used as an antineoplastic agent in the treatment of diseases such as malignant melanomas, Hodgkin’s disease, soft-tissue sarcomas, osteogenic sarcomas, and neuroblastomas.
Advanced Pancreatic Neuroendocrine Tumors (pNET)
Lymphoma, Hodgkins
Metastatic Melanoma
Pheochromocytomas
Advanced Medullary thyroid cancer
Advanced Soft Tissue Sarcoma (STS)

Use in Cancer

Dacarbazine is approved to be used alone or with other drugs to treat:

Hodgkin lymphoma in patients whose disease has not gotten better with other chemotherapy.
Melanoma that has metastasized (spread to other parts of the body).

Dacarbazine is also being studied in the treatment of other types of cancer.

Contraindications

Dacarbazine for Injection is contraindicated in patients who have demonstrated hypersensitivity to it in the past.

decreased function of bone marrow
anemia
decreased blood platelets
low levels of white blood cells
a blood clot in a vein of the liver
liver tissue death
liver problems
decreased kidney function
a patient who is producing milk and breastfeeding

Dosage

Strengths: 100 mg; 200 mg; 500 mg

Malignant Melanoma

2 to 4.5 mg/kg IV once a day for 10 days; repeat every 4 weeks
250 mg/m2 IV once a day for 5 days; repeat every 3 weeks

Hodgkin’s Disease

150 mg/m2 IV once a day for 5 days in combination therapy; repeat every 4 weeks
375 mg/m2 IV on Day 1 in combination therapy; repeat every 15 days

Side effects

The Most Common

nausea, vomiting,
bone marrow suppression,
leukopenia,
platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।" data-rx-term="thrombocytopenia" data-rx-definition="Thrombocytopenia means low platelet count, which can increase bleeding risk. সহজ বাংলা: প্লাটিলেট কম।">thrombocytopenia,
hepatotoxicity,
hepatic vein thrombosis and hepatocellular necrosis.
hemopoietic depression,
anemia, anaphylaxis,
anorexia, diarrhea,
facial paresthesias, death, and rarely,
erythematous and urticarial rashes, and
photosensitivity reactions.
It may cause cardiovascular collapse,
burning of the throat,
abdominal pain, oliguria,
anuria,
delirium,
fall of blood pressure,
convulsions,
muscular weakness with respiratory failure, and collapse.
Large doses may cause gastrointestinal bleeding.
Exposure may also result in alopecia, facial flushing, and a flu-like syndrome of fever, myalgias and malaise.
It can cause chills, dermatological reactions, and neurotoxicity.

More Common

nausea
vomiting
loss of appetite
diarrhea
sores in the mouth and throat
hair loss
the feeling of burning or tingling on the face
flushing
flu-like symptoms
redness, pain, swelling or burning at the site where the injection was given
hives
skin rash
itching
difficulty breathing or swallowing
fever, muscle aches, and general feelings of pain and tiredness

Rare

alopecia,
facial flushing and paraesthesia,
orthostatic hypotension,
ECG abnormalities,
flu-like syndrome,
myalgia,
malaise,
blurred vision,
seizure,
pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।" data-rx-term="headache" data-rx-definition="Headache means pain in the head or upper neck. সহজ বাংলা: মাথাব্যথা।">headache,
confusion,
lethargy,
pain at inj site,
tissue damage,
cellulitis.
photosensitivity,
stomatitis.

Drug Interactions

DRUG	INTERACTION
Abacavir	Dacarbazine may decrease the excretion rate of Abacavir which could result in a higher serum level.
Abametapir	The serum concentration of Dacarbazine can be increased when it is combined with Abametapir.
Abatacept	The metabolism of Dacarbazine can be increased when combined with Abatacept.
Abciximab	The risk or severity of bleeding can be increased when Abciximab is combined with Dacarbazine.
Abiraterone	The serum concentration of Dacarbazine can be increased when it is combined with Abiraterone.
Aceclofenac	Aceclofenac may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Acemetacin	Acemetacin may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Acenocoumarol	The metabolism of Acenocoumarol can be decreased when combined with Dacarbazine.
Acetaminophen	The metabolism of Dacarbazine can be decreased when combined with Acetaminophen.
Acetazolamide	Acetazolamide may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acid	The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Dacarbazine.
Aclidinium	Dacarbazine may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Acrivastine	Dacarbazine may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Acyclovir	The metabolism of Dacarbazine can be decreased when combined with Acyclovir.
Adalimumab	The metabolism of Dacarbazine can be increased when combined with Adalimumab.
Adefovir dipivoxil	Adefovir dipivoxil may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Adenovirus type 7 vaccine live	The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Dacarbazine.
Agomelatine	The metabolism of Agomelatine can be decreased when combined with Dacarbazine.
Albendazole	The metabolism of Dacarbazine can be increased when combined with Albendazole.
Albutrepenonacog alfa	Dacarbazine may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Alclofenac	Alclofenac may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Aldesleukin	The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dacarbazine.
Alefacept	The risk or severity of adverse effects can be increased when Alefacept is combined with Dacarbazine.
Alemtuzumab	The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dacarbazine.
Allogeneic processed thymus tissue	The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Dacarbazine.
Allopurinol	The risk or severity of adverse effects can be increased when Allopurinol is combined with Dacarbazine.
Almasilate	Dacarbazine may decrease the excretion rate of Almasilate which could result in a higher serum level.
Almotriptan	Dacarbazine may decrease the excretion rate of Almotriptan which could result in a higher serum level.
Alogliptin	Dacarbazine may decrease the excretion rate of Alogliptin which could result in a higher serum level.
Alosetron	The metabolism of Dacarbazine can be decreased when combined with Alosetron.
Alprazolam	Alprazolam may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Alteplase	The risk or severity of bleeding can be increased when Alteplase is combined with Dacarbazine.
Altretamine	The risk or severity of adverse effects can be increased when Altretamine is combined with Dacarbazine.
Amantadine	Dacarbazine may decrease the excretion rate of Amantadine which could result in a higher serum level.
Amikacin	Dacarbazine may decrease the excretion rate of Amikacin which could result in a higher serum level.
Amiloride	Amiloride may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.
Aminophenazone	The metabolism of Aminophenazone can be decreased when combined with Dacarbazine.
Aminophylline	The metabolism of Aminophylline can be decreased when combined with Dacarbazine.
Amiodarone	The metabolism of Dacarbazine can be decreased when combined with Amiodarone.
Amitriptyline	The metabolism of Dacarbazine can be decreased when combined with Amitriptyline.
Ammonium chloride	Dacarbazine may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.
Amoxicillin	Dacarbazine may decrease the excretion rate of Amoxicillin which could result in a higher serum level.
Amphetamine	Amphetamine may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Amphotericin B	Amphotericin B may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Ampicillin	Ampicillin may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Amrinone	Dacarbazine may decrease the excretion rate of Amrinone which could result in a higher serum level.
Amsacrine	The risk or severity of adverse effects can be increased when Amsacrine is combined with Dacarbazine.
Anagrelide	The metabolism of Dacarbazine can be decreased when combined with Anagrelide.
Anakinra	The metabolism of Dacarbazine can be increased when combined with Anakinra.
Ancestim	Dacarbazine may decrease the excretion rate of Ancestim which could result in a higher serum level.
Ancrod	The risk or severity of bleeding can be increased when Ancrod is combined with Dacarbazine.
Anifrolumab	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Anifrolumab.
Anistreplase	The risk or severity of bleeding can be increased when Anistreplase is combined with Dacarbazine.
Anthrax immune globulin human	The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Dacarbazine.
Anthrax vaccine	The risk or severity of infection can be increased when Anthrax vaccine is combined with Dacarbazine.
Antihemophilic factor (recombinant), PEGylated	Dacarbazine may decrease the excretion rate of Antihemophilic factor (recombinant), PEGylated which could result in a higher serum level.
Antilymphocyte immunoglobulin (horse)	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Antilymphocyte immunoglobulin (horse).
Antipyrine	The metabolism of Antipyrine can be decreased when combined with Dacarbazine.
Antithrombin Alfa	The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Dacarbazine.
Antithrombin III human	Dacarbazine may decrease the excretion rate of Antithrombin III human which could result in a higher serum level.
Antithymocyte immunoglobulin (rabbit)	The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dacarbazine.
Antrafenine	Antrafenine may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Apalutamide	Dacarbazine may decrease the excretion rate of Apalutamide which could result in a higher serum level.
Apixaban	The risk or severity of bleeding can be increased when Apixaban is combined with Dacarbazine.
Apremilast	The metabolism of Dacarbazine can be increased when combined with Apremilast.
Ardeparin	The risk or severity of bleeding can be increased when Ardeparin is combined with Dacarbazine.
Arformoterol	Dacarbazine may decrease the excretion rate of Arformoterol which could result in a higher serum level.
Argatroban	The risk or severity of bleeding can be increased when Argatroban is combined with Dacarbazine.
Armodafinil	The metabolism of Dacarbazine can be increased when combined with Armodafinil.
Arsenic trioxide	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Arsenic trioxide.
Articaine	The risk or severity of methemoglobinemia can be increased when Dacarbazine is combined with Articaine.
Asenapine	The metabolism of Asenapine can be decreased when combined with Dacarbazine.
AstraZeneca COVID-19 Vaccine	The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Dacarbazine.
Atazanavir	The metabolism of Dacarbazine can be decreased when combined with Atazanavir.
Atomoxetine	Atomoxetine may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Auranofin	Dacarbazine may decrease the excretion rate of Auranofin which could result in a higher serum level.
Aurothioglucose	Dacarbazine may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.
Axitinib	The metabolism of Axitinib can be decreased when combined with Dacarbazine.
Azacitidine	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Azacitidine.
Azathioprine	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Azathioprine.
Azelaic acid	Azelaic acid may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Azelastine	The metabolism of Azelastine can be decreased when combined with Dacarbazine.
Aztreonam	Aztreonam may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Bacillus calmette-guerin substrain connaught live antigen	The risk or severity of infection can be increased when Bacillus Calmette-Guerin substrain Connaught live antigen is combined with Dacarbazine.
Bacillus Calmette-guerin substrain Russian BCG-I live antigen	The therapeutic efficacy of Bacillus Calmette-Guerin substrain Russian BCG-I live antigen can be decreased when used in combination with Dacarbazine.
Bacillus Calmette-Guerin substrain tice live antigen	The risk or severity of infection can be increased when Bacillus Calmette-guerin substrain tice live antigen is combined with Dacarbazine.
Bacitracin	Bacitracin may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Baclofen	Baclofen may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Balsalazide	Balsalazide may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Baricitinib	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Baricitinib.
Basiliximab	The risk or severity of adverse effects can be increased when Basiliximab is combined with Dacarbazine.
BCG vaccine	The risk or severity of infection can be increased when BCG vaccine is combined with Dacarbazine.
Beclomethasone dipropionate	The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Dacarbazine.
Belatacept	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Belatacept.
Belimumab	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Belimumab.
Belinostat	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Belinostat.
Belumosudil	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Belumosudil.
Bemiparin	The risk or severity of bleeding can be increased when Bemiparin is combined with Dacarbazine.
Bendamustine	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Bendamustine.
Bendroflumethiazide	Bendroflumethiazide may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.

Bortezomib	The risk or severity of adverse effects can be increased when Bortezomib is combined with Dacarbazine.
Bosutinib	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Bosutinib.
Brentuximab vedotin	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Brentuximab vedotin.
Brivaracetam	Dacarbazine may decrease the excretion rate of Brivaracetam which could result in a higher serum level.
Brodalumab	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Brodalumab.
Bromazepam	The metabolism of Bromazepam can be decreased when combined with Dacarbazine.
Bromotheophylline	Bromotheophylline may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.
Budesonide	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Budesonide.
Bumadizone	Bumadizone may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Bumetanide	Bumetanide may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.
Bupivacaine	The risk or severity of methemoglobinemia can be increased when Dacarbazine is combined with Bupivacaine.
Bupropion	Dacarbazine may decrease the excretion rate of Bupropion which could result in a higher serum level.
Buspirone	Buspirone may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Busulfan	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Busulfan.
Butabarbital	Butabarbital may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Butacaine	The risk or severity of methemoglobinemia can be increased when Dacarbazine is combined with Butacaine.
Butamben	The risk or severity of methemoglobinemia can be increased when Dacarbazine is combined with Butamben.
Cabazitaxel	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Cabazitaxel.
Caffeine	The metabolism of Dacarbazine can be decreased when combined with Caffeine.
Canagliflozin	Canagliflozin may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.
Canakinumab	The metabolism of Dacarbazine can be increased when combined with Canakinumab.
Cangrelor	The risk or severity of bleeding can be increased when Cangrelor is combined with Dacarbazine.
Cannabidiol	The metabolism of Dacarbazine can be decreased when combined with Cannabidiol.
Canrenoic acid	Canrenoic acid may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.
Capecitabine	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Capecitabine.
Caplacizumab	The risk or severity of bleeding can be increased when Caplacizumab is combined with Dacarbazine.
Capmatinib	The serum concentration of Dacarbazine can be increased when it is combined with Capmatinib.
Capreomycin	Dacarbazine may decrease the excretion rate of Capreomycin which could result in a higher serum level.
Capsaicin	The risk or severity of methemoglobinemia can be increased when Dacarbazine is combined with Capsaicin.
Carbamazepine	The risk or severity of adverse effects can be increased when Carbamazepine is combined with Dacarbazine.
Carbidopa	Carbidopa may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Carboplatin	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Carboplatin.
Carfilzomib	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Carfilzomib.
Carmustine	The risk or severity of adverse effects can be increased when Carmustine is combined with Dacarbazine.
Carprofen	Carprofen may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Carvedilol	The metabolism of Carvedilol can be decreased when combined with Dacarbazine.
Cefaclor	Cefaclor may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Cefadroxil	Cefadroxil may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Cefalotin	Cefalotin may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Cefamandole	Cefamandole may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Cefapirin	Cefapirin may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Cefazolin	Cefazolin may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Cefdinir	Cefdinir may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Cefditoren	Cefditoren may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Cefepime	Cefepime may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Cefmenoxime	Cefmenoxime may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Cefmetazole	Cefmetazole may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Cefonicid	Cefonicid may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Cefoperazone	Cefoperazone may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Ceforanide	Ceforanide may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Cefotaxime	Cefotaxime may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Cefotetan	Cefotetan may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Cefotiam	Cefotiam may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Cefoxitin	Cefoxitin may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Cefpiramide	Cefpiramide may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Cefpirome	Cefpirome may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Cefpodoxime	Cefpodoxime may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Cefprozil	Cefprozil may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Cefradine	Cefradine may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Ceftaroline fosamil	Ceftaroline fosamil may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Ceftazidime	Ceftazidime may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Ceftibuten	Ceftibuten may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Ceftizoxime	Ceftizoxime may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Ceftobiprole	Ceftobiprole may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Ceftolozane	Dacarbazine may decrease the excretion rate of Ceftolozane which could result in a higher serum level.
Ceftriaxone	Ceftriaxone may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Cefuroxime	Cefuroxime may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Celecoxib	Celecoxib may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Cephalexin	Cephalexin may decrease the excretion rate of Dacarbazine which could result in a higher serum level.

Cyanocobalamin	The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Dacarbazine.
Cyclobenzaprine	The metabolism of Cyclobenzaprine can be decreased when combined with Dacarbazine.
Cyclopenthiazide	Cyclopenthiazide may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.
Cyclophosphamide	The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Dacarbazine.
Cyclosporine	Dacarbazine may increase the immunosuppressive activities of Cyclosporine.
Cyclothiazide	Cyclothiazide may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.
Cyproterone acetate	The metabolism of Dacarbazine can be increased when combined with Cyproterone acetate.
Cytarabine	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Cytarabine.
Dabigatran	The risk or severity of bleeding can be increased when Dabigatran is combined with Dacarbazine.
Dabigatran etexilate	Dacarbazine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.
Dactinomycin	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Dactinomycin.
Dalfampridine	Dacarbazine may decrease the excretion rate of Dalfampridine which could result in a higher serum level.
Dalteparin	The risk or severity of bleeding can be increased when Dalteparin is combined with Dacarbazine.
Danaparoid	The risk or severity of bleeding can be increased when Danaparoid is combined with Dacarbazine.
Dapagliflozin	The metabolism of Dacarbazine can be decreased when combined with Dapagliflozin.
Daptomycin	Daptomycin may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Darbepoetin alfa	The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Dacarbazine.
Dasatinib	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Dasatinib.
Daunorubicin	The risk or severity of adverse effects can be increased when Daunorubicin is combined with Dacarbazine.
Decitabine	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Decitabine.
Deferasirox	The serum concentration of Dacarbazine can be increased when it is combined with Deferasirox.
Deferiprone	Dacarbazine may decrease the excretion rate of Deferiprone which could result in a higher serum level.
Defibrotide	The risk or severity of bleeding can be increased when Defibrotide is combined with Dacarbazine.
Deflazacort	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Deflazacort.
Delafloxacin	Dacarbazine may decrease the excretion rate of Delafloxacin which could result in a higher serum level.
Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Dacarbazine.
Desipramine	Dacarbazine may decrease the excretion rate of Desipramine which could result in a higher serum level.
Desirudin	The risk or severity of bleeding can be increased when Desirudin is combined with Dacarbazine.
Desmopressin	Desmopressin may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Desoximetasone	The risk or severity of adverse effects can be increased when Desoximetasone is combined with Dacarbazine.
Desvenlafaxine	Dacarbazine may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.
Deucravacitinib	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Deucravacitinib.
Deutetrabenazine	Dacarbazine may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.
Dexamethasone	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Dexamethasone.
Dexfenfluramine	The metabolism of Dexfenfluramine can be decreased when combined with Dacarbazine.
Dexibuprofen	Dexibuprofen may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Dexketoprofen	Dexketoprofen may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Dexmedetomidine	The metabolism of Dacarbazine can be decreased when combined with Dexmedetomidine.
Dexpanthenol	Dacarbazine may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.
Dexrazoxane	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Dacarbazine.
Dextran	Dacarbazine may decrease the excretion rate of Dextran which could result in a higher serum level.
Diacerein	The metabolism of Dacarbazine can be decreased when combined with Diacerein.
Diatrizoate	Diatrizoate may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Diazepam	Diazepam may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Dichlorobenzyl alcohol	Dacarbazine may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.
Diclofenac	The metabolism of Dacarbazine can be decreased when combined with Diclofenac.
Diclofenamide	Diclofenamide may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.

Eculizumab	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Eculizumab.
Edetic acid	The risk or severity of bleeding can be increased when Edetic acid is combined with Dacarbazine.
Edoxaban	Dacarbazine may decrease the excretion rate of Edoxaban which could result in a higher serum level.
Edrophonium	Dacarbazine may decrease the excretion rate of Edrophonium which could result in a higher serum level.
Efalizumab	The risk or severity of adverse effects can be increased when Efalizumab is combined with Dacarbazine.
Efavirenz	The metabolism of Dacarbazine can be decreased when combined with Efavirenz.
Eltrombopag	The metabolism of Eltrombopag can be decreased when combined with Dacarbazine.
Emapalumab	The metabolism of Dacarbazine can be increased when combined with Emapalumab.
Enalaprilat	Dacarbazine may decrease the excretion rate of Enalaprilat which could result in a higher serum level.
Enasidenib	The metabolism of Dacarbazine can be decreased when combined with Enasidenib.
Enoxacin	The metabolism of Dacarbazine can be decreased when combined with Enoxacin.
Enoxaparin	The risk or severity of bleeding can be increased when Enoxaparin is combined with Dacarbazine.
Entecavir	The metabolism of Dacarbazine can be decreased when combined with Entecavir.
Enzalutamide	Dacarbazine may decrease the excretion rate of Enzalutamide which could result in a higher serum level.
Epirubicin	The risk or severity of adverse effects can be increased when Epirubicin is combined with Dacarbazine.
Eplerenone	Eplerenone may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.
Epoprostenol	The risk or severity of bleeding can be increased when Epoprostenol is combined with Dacarbazine.
Eptifibatide	The risk or severity of bleeding can be increased when Eptifibatide is combined with Dacarbazine.
Eribulin	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Eribulin.
Erlotinib	The metabolism of Dacarbazine can be decreased when combined with Erlotinib.
Ertapenem	Ertapenem may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Ertugliflozin	Ertugliflozin may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.
Erythropoietin	The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Dacarbazine.
Estazolam	Dacarbazine may decrease the excretion rate of Estazolam which could result in a higher serum level.
Estradiol	The metabolism of Dacarbazine can be decreased when combined with Estradiol.
Estradiol acetate	The metabolism of Dacarbazine can be decreased when combined with Estradiol acetate.
Estradiol benzoate	The metabolism of Dacarbazine can be decreased when combined with Estradiol benzoate.
Estradiol cypionate	The metabolism of Estradiol cypionate can be decreased when combined with Dacarbazine.
Estradiol dienanthate	The metabolism of Dacarbazine can be decreased when combined with Estradiol dienanthate.
Estradiol valerate	The metabolism of Dacarbazine can be decreased when combined with Estradiol valerate.
Estramustine	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Estramustine.
Estrone sulfate	The metabolism of Dacarbazine can be decreased when combined with Estrone sulfate.
Eszopiclone	Eszopiclone may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Etacrynic acid	Etacrynic acid may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.
Etafedrine	Dacarbazine may decrease the excretion rate of Etafedrine which could result in a higher serum level.
Etanercept	The metabolism of Dacarbazine can be increased when combined with Etanercept.
Ethambutol	The metabolism of Dacarbazine can be decreased when combined with Ethambutol.
Ethanol	The metabolism of Ethanol can be decreased when combined with Dacarbazine.
Ethinylestradiol	The metabolism of Ethinylestradiol can be decreased when combined with Dacarbazine.
Ethyl chloride	The risk or severity of methemoglobinemia can be increased when Dacarbazine is combined with Ethyl chloride.
Etidocaine	The risk or severity of methemoglobinemia can be increased when Dacarbazine is combined with Etidocaine.
Etodolac	Etodolac may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Etomidate	Etomidate may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Etonogestrel	Etonogestrel may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Etoposide	The risk or severity of adverse effects can be increased when Etoposide is combined with Dacarbazine.
Etoricoxib	The metabolism of Etoricoxib can be decreased when combined with Dacarbazine.
Eucalyptus oil	Dacarbazine may decrease the excretion rate of Eucalyptus oil which could result in a higher serum level.
Everolimus	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Everolimus.
Ezogabine	Dacarbazine may decrease the excretion rate of Ezogabine which could result in a higher serum level.
Famotidine	The metabolism of Dacarbazine can be decreased when combined with Famotidine.
Fenbufen	Fenbufen may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Fenfluramine	The metabolism of Dacarbazine can be decreased when combined with Fenfluramine.
Fenofibrate	Dacarbazine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.
Fenofibric acid	Dacarbazine may decrease the excretion rate of Fenofibric acid which could result in a higher serum level.
Fenoldopam	Fenoldopam may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Fenoprofen	Fenoprofen may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Fentanyl	Fentanyl may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Fesoterodine	Dacarbazine may decrease the excretion rate of Fesoterodine which could result in a higher serum level.
Fexinidazole	The metabolism of Dacarbazine can be decreased when combined with Fexinidazole.
Filgotinib	The serum concentration of Dacarbazine can be increased when it is combined with Filgotinib.
Finerenone	Finerenone may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.
Fingolimod	Dacarbazine may increase the immunosuppressive activities of Fingolimod.
Flavoxate	Dacarbazine may decrease the excretion rate of Flavoxate which could result in a higher serum level.
Flecainide	The metabolism of Flecainide can be decreased when combined with Dacarbazine.

Fluoxetine	The metabolism of Dacarbazine can be decreased when combined with Fluoxetine.
Flupentixol	The risk or severity of myelosuppression can be increased when Flupentixol is combined with Dacarbazine.
Fluprednisolone	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Fluprednisolone.
Flurazepam	Flurazepam may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Flurbiprofen	Flurbiprofen may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Flutamide	The metabolism of Dacarbazine can be decreased when combined with Flutamide.
Fluticasone	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Fluticasone.
Fluticasone furoate	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Fluticasone furoate.
Fluticasone propionate	The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Dacarbazine.
Fluvoxamine	The metabolism of Dacarbazine can be decreased when combined with Fluvoxamine.
Folic acid	Folic acid may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Fomepizole	Dacarbazine may decrease the excretion rate of Fomepizole which could result in a higher serum level.
Fondaparinux	Fondaparinux may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Formestane	Dacarbazine may decrease the excretion rate of Formestane which could result in a higher serum level.
Foscarnet	Foscarnet may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Fosfomycin	Fosfomycin may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Fosinopril	Fosinopril may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Fosphenytoin	The metabolism of Dacarbazine can be increased when combined with Fosphenytoin.
Framycetin	Framycetin may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Frovatriptan	The metabolism of Frovatriptan can be decreased when combined with Dacarbazine.
Furosemide	Furosemide may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.
Gabapentin enacarbil	Dacarbazine may decrease the excretion rate of Gabapentin enacarbil which could result in a higher serum level.
Gadobenic acid	Gadobenic acid may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Gadodiamide	Gadodiamide may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Gadofosveset trisodium	Dacarbazine may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.
Gadopentetic acid	Gadopentetic acid may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Gadoteric acid	Dacarbazine may decrease the excretion rate of Gadoteric acid which could result in a higher serum level.
Gadoteridol	Gadoteridol may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Gallium nitrate	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Gallium nitrate.
Ganciclovir	Dacarbazine may decrease the excretion rate of Ganciclovir which could result in a higher serum level.
Gatifloxacin	The metabolism of Dacarbazine can be decreased when combined with Gatifloxacin.
Gemcitabine	The risk or severity of adverse effects can be increased when Gemcitabine is combined with Dacarbazine.
Gemfibrozil	The metabolism of Dacarbazine can be decreased when combined with Gemfibrozil.
Gemifloxacin	The metabolism of Dacarbazine can be decreased when combined with Gemifloxacin.
Gemtuzumab ozogamicin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dacarbazine.
Gentamicin	Dacarbazine may decrease the excretion rate of Gentamicin which could result in a higher serum level.
Gimeracil	Dacarbazine may decrease the excretion rate of Gimeracil which could result in a higher serum level.
Givosiran	The serum concentration of Dacarbazine can be increased when it is combined with Givosiran.
Glatiramer	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Glatiramer.
Glipizide	Dacarbazine may decrease the excretion rate of Glipizide which could result in a higher serum level.
Glycerol phenylbutyrate	Dacarbazine may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.
Golimumab	The metabolism of Dacarbazine can be increased when combined with Golimumab.
Golodirsen	Dacarbazine may decrease the excretion rate of Golodirsen which could result in a higher serum level.
Goserelin	Goserelin may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Grepafloxacin	The metabolism of Dacarbazine can be decreased when combined with Grepafloxacin.
Guanabenz	The metabolism of Dacarbazine can be decreased when combined with Guanabenz.
Guanethidine	Dacarbazine may decrease the excretion rate of Guanethidine which could result in a higher serum level.
Guanfacine	Dacarbazine may decrease the excretion rate of Guanfacine which could result in a higher serum level.
Guselkumab	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Guselkumab.
Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen	The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Dacarbazine.
Haloperidol	The metabolism of Dacarbazine can be decreased when combined with Haloperidol.
Heparin	The risk or severity of bleeding can be increased when Heparin is combined with Dacarbazine.
Hepatitis A Vaccine	The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Dacarbazine.
Hepatitis B Vaccine (Recombinant)	The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Dacarbazine.
Human adenovirus e serotype 4 strain cl-68578 antigen	The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Dacarbazine.
Hydralazine	Dacarbazine may decrease the excretion rate of Hydralazine which could result in a higher serum level.
Hydrochlorothiazide	Hydrochlorothiazide may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.
Hydrocortisone acetate	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Hydrocortisone acetate.
Hydrocortisone butyrate	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Hydrocortisone butyrate.
Hydrocortisone succinate	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Hydrocortisone succinate.
Hydroflumethiazide	Hydroflumethiazide may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.
Hydromorphone	Hydromorphone may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Hydroxocobalamin	Hydroxocobalamin may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Hydroxychloroquine	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Hydroxychloroquine.
Hydroxyethyl Starch	Dacarbazine may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.
Hydroxyurea	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Hydroxyurea.
Ibritumomab tiuxetan	The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dacarbazine.
Ibrutinib	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Ibrutinib.
Ibuprofen	Ibuprofen may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Ibutilide	Ibutilide may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Icatibant	Dacarbazine may decrease the excretion rate of Icatibant which could result in a higher serum level.
Icosapent	Icosapent may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Icosapent ethyl	The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Dacarbazine.
Idarubicin	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Idarubicin.
Idarucizumab	Dacarbazine may decrease the excretion rate of Idarucizumab which could result in a higher serum level.
Idebenone	Dacarbazine may decrease the excretion rate of Idebenone which could result in a higher serum level.
Idelalisib	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Idelalisib.
Ifosfamide	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Ifosfamide.
Iloprost	The risk or severity of bleeding can be increased when Iloprost is combined with Dacarbazine.
Imatinib	The risk or severity of adverse effects can be increased when Imatinib is combined with Dacarbazine.
Imipramine	The metabolism of Dacarbazine can be decreased when combined with Imipramine.
Indapamide	Indapamide may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.

Mefenamic acid	The metabolism of Dacarbazine can be decreased when combined with Mefenamic acid.
Megestrol acetate	Megestrol acetate may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Melatonin	The metabolism of Melatonin can be decreased when combined with Dacarbazine.
Meloxicam	The risk or severity of methemoglobinemia can be increased when Dacarbazine is combined with Meloxicam.
Melphalan	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Melphalan.
Memantine	Dacarbazine may decrease the excretion rate of Memantine which could result in a higher serum level.
Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine	The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Dacarbazine.
Meperidine	Meperidine may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Mephenytoin	The metabolism of Dacarbazine can be decreased when combined with Mephenytoin.
Mepivacaine	The risk or severity of methemoglobinemia can be increased when Dacarbazine is combined with Mepivacaine.
Mepolizumab	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Mepolizumab.
Meprednisone	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Meprednisone.
Mercaptopurine	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Mercaptopurine.
Meropenem	Meropenem may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Mesalazine	Mesalazine may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Metamfetamine	Dacarbazine may decrease the excretion rate of Metamfetamine which could result in a higher serum level.
Metamizole	Metamizole may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Metaxalone	Metaxalone may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Metformin	Metformin may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Methadone	Methadone may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Methazolamide	Methazolamide may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.
Methimazole	The risk or severity of adverse effects can be increased when Methimazole is combined with Dacarbazine.
Methotrexate	The risk or severity of adverse effects can be increased when Methotrexate is combined with Dacarbazine.
Methoxsalen	The metabolism of Dacarbazine can be decreased when combined with Methoxsalen.
Methoxy polyethylene glycol-epoetin beta	The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Dacarbazine.
Methyldopa	Dacarbazine may decrease the excretion rate of Methyldopa which could result in a higher serum level.
Methylene blue	The metabolism of Dacarbazine can be increased when combined with Methylene blue.
Methylnaltrexone	Dacarbazine may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.
Methylprednisolone	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Methylprednisolone.
Methyltestosterone	Dacarbazine may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.
Meticrane	Meticrane may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.
Metoclopramide	The metabolism of Metoclopramide can be decreased when combined with Dacarbazine.
Metolazone	Metolazone may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.
Metoprolol	Metoprolol may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Metyrapone	Dacarbazine may decrease the excretion rate of Metyrapone which could result in a higher serum level.
Mexiletine	The metabolism of Dacarbazine can be decreased when combined with Mexiletine.
Mianserin	The metabolism of Mianserin can be decreased when combined with Dacarbazine.
Midazolam	Midazolam may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Migalastat	Dacarbazine may decrease the excretion rate of Migalastat which could result in a higher serum level.
Milnacipran	Dacarbazine may decrease the excretion rate of Milnacipran which could result in a higher serum level.
Milrinone	Milrinone may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Mirabegron	Dacarbazine may decrease the excretion rate of Mirabegron which could result in a higher serum level.
Mirtazapine	The metabolism of Dacarbazine can be decreased when combined with Mirtazapine.
Mitomycin	The risk or severity of adverse effects can be increased when Mitomycin is combined with Dacarbazine.
Mitoxantrone	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Mitoxantrone.
Moderna COVID-19 Vaccine	The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Dacarbazine.
Modified vaccinia ankara	The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Dacarbazine.
Mometasone furoate	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Mometasone furoate.
Monomethyl fumarate	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Monomethyl fumarate.
Mosunetuzumab	The metabolism of Dacarbazine can be decreased when combined with Mosunetuzumab.
Moxifloxacin	The metabolism of Dacarbazine can be decreased when combined with Moxifloxacin.
Moxisylyte	Dacarbazine may decrease the excretion rate of Moxisylyte which could result in a higher serum level.
Mumps virus strain B level jeryl lynn live antigen	The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Dacarbazine.
Muromonab	The risk or severity of adverse effects can be increased when Muromonab is combined with Dacarbazine.
Muzolimine	Muzolimine may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.
Mycophenolate mofetil	The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Dacarbazine.
Mycophenolic acid	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Mycophenolic acid.
N-acetyltyrosine	Dacarbazine may decrease the excretion rate of N-acetyltyrosine which could result in a higher serum level.
Nabumetone	The metabolism of Dacarbazine can be decreased when combined with Nabumetone.
Nadolol	Dacarbazine may decrease the excretion rate of Nadolol which could result in a higher serum level.
Nadroparin	The risk or severity of bleeding can be increased when Nadroparin is combined with Dacarbazine.
Nafcillin	The metabolism of Dacarbazine can be increased when combined with Nafcillin.
Naldemedine	Dacarbazine may decrease the excretion rate of Naldemedine which could result in a higher serum level.
Nalidixic acid	The metabolism of Dacarbazine can be decreased when combined with Nalidixic acid.
Nalmefene	Dacarbazine may decrease the excretion rate of Nalmefene which could result in a higher serum level.
Naloxone	Dacarbazine may decrease the excretion rate of Naloxone which could result in a higher serum level.
Naproxen	The metabolism of Dacarbazine can be decreased when combined with Naproxen.
Natalizumab	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Natalizumab.
Nateglinide	Nateglinide may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Nedaplatin	Dacarbazine may decrease the excretion rate of Nedaplatin which could result in a higher serum level.
Nedocromil	Nedocromil may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Nefazodone	Dacarbazine may decrease the excretion rate of Nefazodone which could result in a higher serum level.
Nelarabine	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Nelarabine.
Neomycin	Dacarbazine may decrease the excretion rate of Neomycin which could result in a higher serum level.
Netilmicin	Dacarbazine may decrease the excretion rate of Netilmicin which could result in a higher serum level.
Nevirapine	The metabolism of Dacarbazine can be decreased when combined with Nevirapine.
Niclosamide	The metabolism of Dacarbazine can be decreased when combined with Niclosamide.
Nicorandil	Dacarbazine may decrease the excretion rate of Nicorandil which could result in a higher serum level.
Nifedipine	The metabolism of Nifedipine can be decreased when combined with Dacarbazine.
Nilotinib	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Nilotinib.
Nilutamide	Nilutamide may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Nimesulide	The risk or severity of bleeding can be increased when Nimesulide is combined with Dacarbazine.
Nisoldipine	Nisoldipine may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Nitric Oxide	Nitric Oxide may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Nitrofurantoin	Nitrofurantoin may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Nitroprusside	Nitroprusside may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Norfloxacin	The metabolism of Dacarbazine can be decreased when combined with Norfloxacin.
Nuvaxovid	The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Dacarbazine.
Obeticholic acid	The risk or severity of adverse effects can be increased when Obeticholic acid is combined with Dacarbazine.
Obinutuzumab	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Obinutuzumab.

Zotepine	The metabolism of Zotepine can be decreased when combined with Dacarbazine.
Zonisamide	Zonisamide may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.
Zolpidem	The metabolism of Dacarbazine can be decreased when combined with Zolpidem.
Zolmitriptan	The metabolism of Dacarbazine can be decreased when combined with Zolmitriptan.
Zileuton	The metabolism of Dacarbazine can be decreased when combined with Zileuton.
Zidovudine	The risk or severity of adverse effects can be increased when Zidovudine is combined with Dacarbazine.
Zanamivir	Zanamivir may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Zaleplon	Dacarbazine may decrease the excretion rate of Zaleplon which could result in a higher serum level.
Yellow fever vaccine	The risk or severity of infection can be increased when Yellow fever vaccine is combined with Dacarbazine.
Ximelagatran	The risk or severity of bleeding can be increased when Ximelagatran is combined with Dacarbazine.
Warfarin	The metabolism of Dacarbazine can be decreased when combined with Warfarin.
Voxilaprevir	The metabolism of Voxilaprevir can be decreased when combined with Dacarbazine.
Vortioxetine	Dacarbazine may decrease the excretion rate of Vortioxetine which could result in a higher serum level.
Vorinostat	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Vorinostat.
Vorapaxar	The risk or severity of bleeding can be increased when Vorapaxar is combined with Dacarbazine.
Voclosporin	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Voclosporin.
Vinorelbine	The risk or severity of adverse effects can be increased when Vinorelbine is combined with Dacarbazine.
Vindesine	The risk or severity of adverse effects can be increased when Vindesine is combined with Dacarbazine.
Vincristine	The risk or severity of adverse effects can be increased when Vincristine is combined with Dacarbazine.
Vinblastine	The risk or severity of adverse effects can be increased when Vinblastine is combined with Dacarbazine.
Viloxazine	The metabolism of Dacarbazine can be decreased when combined with Viloxazine.
Vilanterol	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Vilanterol.
Vibrio cholerae CVD 103-HgR strain live antigen	The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Dacarbazine.
Verapamil	The metabolism of Dacarbazine can be decreased when combined with Verapamil.
Venlafaxine	Venlafaxine may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Vemurafenib	The serum concentration of Dacarbazine can be increased when it is combined with Vemurafenib.
Vedolizumab	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Vedolizumab.
Varicella zoster vaccine (recombinant)	The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Dacarbazine.
Varicella zoster vaccine (live/attenuated)	The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Dacarbazine.
Varenicline	Dacarbazine may decrease the excretion rate of Varenicline which could result in a higher serum level.
Vancomycin	Dacarbazine may decrease the excretion rate of Vancomycin which could result in a higher serum level.
Valproic acid	The metabolism of Dacarbazine can be decreased when combined with Valproic acid.
Valganciclovir	Dacarbazine may decrease the excretion rate of Valganciclovir which could result in a higher serum level.
Valdecoxib	Valdecoxib may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Valbenazine	Dacarbazine may decrease the excretion rate of Valbenazine which could result in a higher serum level.
Valaciclovir	Valaciclovir may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Vaborbactam	Dacarbazine may decrease the excretion rate of Vaborbactam which could result in a higher serum level.
Urokinase	The risk or severity of bleeding can be increased when Urokinase is combined with Dacarbazine.
Upadacitinib	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Upadacitinib.
Typhoid Vi polysaccharide vaccine	The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Dacarbazine.
Typhoid Vaccine Live	The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Dacarbazine.
Typhoid vaccine	The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Dacarbazine.
Trovafloxacin	The metabolism of Dacarbazine can be decreased when combined with Trovafloxacin.
Tropisetron	Dacarbazine may decrease the excretion rate of Tropisetron which could result in a higher serum level.
Trimetrexate	Dacarbazine may decrease the excretion rate of Trimetrexate which could result in a higher serum level.
Trimethoprim	Trimethoprim may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Trimebutine	Dacarbazine may decrease the excretion rate of Trimebutine which could result in a higher serum level.
Trilostane	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Trilostane.
Trilaciclib	The metabolism of Dacarbazine can be increased when combined with Trilaciclib.
Triflusal	The risk or severity of bleeding can be increased when Triflusal is combined with Dacarbazine.
Trifluridine	The risk or severity of adverse effects can be increased when Trifluridine is combined with Dacarbazine.
Trifluoperazine	The metabolism of Dacarbazine can be decreased when combined with Trifluoperazine.
Triethylenetetramine	Dacarbazine may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.
Triclabendazole	The metabolism of Dacarbazine can be decreased when combined with Triclabendazole.
Trichlormethiazide	Trichlormethiazide may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.
Triazolam	Dacarbazine may decrease the excretion rate of Triazolam which could result in a higher serum level.
Triamterene	Triamterene may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.
Triamcinolone	The risk or severity of adverse effects can be increased when Triamcinolone is combined with Dacarbazine.
Tretinoin	The risk or severity of adverse effects can be increased when Tretinoin is combined with Dacarbazine.
Trastuzumab emtansine	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Trastuzumab emtansine.
Trastuzumab	Trastuzumab may increase the neutropenic activities of Dacarbazine.
Trametinib	Dacarbazine may decrease the excretion rate of Trametinib which could result in a higher serum level.
Tramadol	Tramadol may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Trabectedin	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Trabectedin.
Tositumomab	The risk or severity of adverse effects can be increased when Tositumomab is combined with Dacarbazine.
Torasemide	Torasemide may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.
Topotecan	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Topotecan.
Topiramate	Topiramate may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Tolvaptan	Tolvaptan may increase the excretion rate of Dacarbazine which could result in a lower serum level and potentially a reduction in efficacy.
Tolterodine	Dacarbazine may decrease the excretion rate of Tolterodine which could result in a higher serum level.
Tolmetin	Tolmetin may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Tolfenamic acid	Tolfenamic acid may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Tolcapone	Tolcapone may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Tolbutamide	Dacarbazine may decrease the excretion rate of Tolbutamide which could result in a higher serum level.
Tolazamide	Tolazamide may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Tofacitinib	Dacarbazine may increase the immunosuppressive activities of Tofacitinib.
Tocopherol	Dacarbazine may decrease the excretion rate of Tocopherol which could result in a higher serum level.
Tocilizumab	The metabolism of Dacarbazine can be increased when combined with Tocilizumab.
Tocainide	The metabolism of Dacarbazine can be decreased when combined with Tocainide.
Tobramycin	Dacarbazine may decrease the excretion rate of Tobramycin which could result in a higher serum level.
Tizanidine	The metabolism of Dacarbazine can be decreased when combined with Tizanidine.
Tixocortol	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Tixocortol.
Tirofiban	The risk or severity of bleeding can be increased when Tirofiban is combined with Dacarbazine.
Tiotropium	Dacarbazine may decrease the excretion rate of Tiotropium which could result in a higher serum level.
Tiopronin	Dacarbazine may decrease the excretion rate of Tiopronin which could result in a higher serum level.
Tioguanine	The risk or severity of adverse effects can be increased when Tioguanine is combined with Dacarbazine.
Tinzaparin	The risk or severity of bleeding can be increased when Tinzaparin is combined with Dacarbazine.
Tinidazole	Dacarbazine may decrease the excretion rate of Tinidazole which could result in a higher serum level.
Timolol	Timolol may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Tiludronic acid	Dacarbazine may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.
Ticlopidine	The metabolism of Dacarbazine can be decreased when combined with Ticlopidine.
Tick-borne encephalitis vaccine (whole virus, inactivated)	The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Dacarbazine.
Ticagrelor	The risk or severity of bleeding can be increased when Ticagrelor is combined with Dacarbazine.
Tiaprofenic acid	Tiaprofenic acid may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Thiothixene	The metabolism of Thiothixene can be decreased when combined with Dacarbazine.
Thiotepa	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Thiotepa.
Thiethylperazine	Thiethylperazine may decrease the excretion rate of Dacarbazine which could result in a higher serum level.
Thiabendazole	The metabolism of Dacarbazine can be decreased when combined with Thiabendazole.
Theophylline	The metabolism of Dacarbazine can be decreased when combined with Theophylline.
Thalidomide	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Thalidomide.

Pregnancy and Lactation

Pregnancy

Pregnancy Category C:

Dacarbazine for Injection has been shown to be teratogenic in rats when given in doses 20 times the human daily dose on day 12 of gestation. Dacarbazine when administered in 10 times the human daily dose to male rats (twice weekly for 9 weeks) did not affect the male libido, although female rats mated to male rats had a higher incidence of resorptions than controls. In rabbits, dacarbazine daily dose 7 times the human daily dose given on Days 6 to 15 of gestation resulted in fetal skeletal anomalies. There are no adequate and well-controlled studies in pregnant women. Dacarbazine for Injection should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for tumorigenicity shown for Dacarbazine for Injection in animal studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Lactation

Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy, especially alkylating agents such as dacarbazine.[1] It might be possible to breastfeed safely during intermittent therapy with an appropriate period of breastfeeding abstinence; however, no data are available to determine an appropriate period to withhold breastfeeding. Chemotherapy may adversely affect the normal microbiome and chemical makeup of breast milk. Women who receive chemotherapy during pregnancy are more likely to have difficulty nursing their infant.

What special precautions should I follow?

Before receiving dacarbazine,

tell your doctor and pharmacist if you are allergic to dacarbazine, any other medications, or any of the ingredients in dacarbazine injection. Ask your pharmacist for a list of the ingredients.
tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take.
tell your doctor if you are breastfeeding.
plan to avoid unnecessary or prolonged exposure to sunlight and to wear protective clothing, sunglasses, and sunscreen. Dacarbazine may make your skin sensitive to sunlight.

WARNINGS

Hemopoietic depression is the most common toxicity with Dacarbazine for Injection and involves primarily the leukocytes and platelets, although, anemia may sometimes occur. Leukopenia and thrombocytopenia may be severe enough to cause death. Possible bone marrow depression requires careful monitoring of white blood cells, red blood cells, and platelet levels. Hemopoietic toxicity may warrant temporary suspension or cessation of therapy with Dacarbazine for Injection.

Hepatic toxicity accompanied by hepatic vein thrombosis and hepatocellular necrosis resulting in death has been reported. The incidence of such reactions has been low; approximately 0.01% of patients were treated. This toxicity has been observed mostly when Dacarbazine for Injection has been administered concomitantly with other anti-neoplastic drugs: however, it has also been reported in some patients treated with Dacarbazine for Injection alone.

Anaphylaxis can occur following the administration of Dacarbazine for Injection.

Hospitalization is not always necessary but adequate laboratory study capability must be available. Extravasation of the drug subcutaneously during intravenous administration may result in tissue damage and severe pain. Local pain, burning sensation, and irritation at the site of injection may be relieved by locally applied hot packs.

The carcinogenicity of dacarbazine was studied in rats and mice. Proliferative endocardial lesions, including fibrosarcomas and sarcomas, were induced by dacarbazine in rats. In mice, administration of dacarbazine resulted in the induction of angiosarcomas of the spleen.

References

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

Write when the problem started and how it changed.
Bring old prescriptions, investigation reports, and current medicines.
Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

What is the most likely cause of my symptoms?
Which danger signs mean I should go to hospital quickly?
Which tests are necessary now, and which can wait?
How should I take medicines safely and what side effects should I watch for?
When should I come for follow-up?

Tests to discuss

Vital signs: temperature, pulse, blood pressure, oxygen saturation
Basic physical examination by a clinician
CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

Avoid heavy lifting, sudden bending, and prolonged bed rest.
Use comfortable posture and gentle movement as tolerated.
Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

Do not start antibiotics without a proper medical decision.
Do not use steroid tablets or injections casually for quick relief.
Do not delay emergency care because of home remedies.

Get urgent help if

Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.

Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Medicine doctor / pediatrician for children / qualified clinician

Tests to discuss with doctor

Temperature chart and hydration assessment
CBC with platelet count if fever persists or dengue/other infection is possible
Urine test, malaria/dengue tests, chest evaluation, or blood culture only when clinically indicated

Questions to ask

What is the most likely cause of my symptoms?
Which warning signs mean I should go to emergency care?
Which tests are really needed now?
Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
Do I need antibiotics, or is this more likely viral?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Go to emergency care if you notice:

Severe or rapidly worsening symptoms
Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration

Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.

Step 1
Check danger signs first

If danger signs are present, seek emergency care and do not wait for online information.
Step 2
Record the symptom story

Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.
Step 3
Visit a qualified clinician

A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.
Step 4
Do only useful tests

Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.
Step 5
Follow up and return early if worse

If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips

Take a written symptom diary and all previous prescriptions/test reports.
Do not hide medicines already taken, even herbal or over-the-counter medicines.
Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Website

Name or nickname Phone / contact District / area Age group Sex Severity today

Main symptoms How long has it been happening? Medicines already taken Tests already done Your question 0/1200

Frequently Asked Questions

Is this article a replacement for a doctor?

No. It is educational content only. Patients should consult a qualified clinician for diagnosis and treatment.

When should I seek urgent care?

Seek urgent care for severe symptoms, rapidly worsening condition, breathing difficulty, severe pain, neurological changes, or any emergency warning sign.

References

Add references, clinical guidelines, textbooks, journal articles, or trusted medical sources here. You can edit this area from the RX Article Professional Blocks panel.

Read, save, and share this guide

Understand this article easily